A recent study on pre-treatment and post-treatment biopsies from 12 patients who received cemiplimab (an anti-PD1 therapy) showed that responder patients displayed decreased T helper and CD4+ T-cells in tumor specimens after anti-PD1 therapy, along with downregulation of Tumor Necrosis Factor signaling, IL-1 β, and IL-8, whereas CD8+ T-cells and B cells increased. Here, CD8A is linked to neoplasm.